AI Healthtech Firm Partners with EngageWell and CVS Health Foundation on NYC Senior Care Initiative

1. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Treatment.com AI.
2. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
3.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
4. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

* Disclosure for the quote from the Clive Maund article published on May 21, 2025

1. For the quoted article (published on May 21, 2025), the Company has paid Street Smart, an affiliate of Streetwise Reports, US$1,500.
2. Author Certification and Compensation: [Clive Maund of clivemaund.com] is being compensated as an independent contractor by Street Smart, an affiliate of Streetwise Reports, for writing the article quoted. Maund received his UK Technical Analysts’ Diploma in 1989.  The recommendations and opinions expressed in the article accurately reflect the personal, independent, and objective views of the author regarding any and all of the designated securities discussed. No part of the compensation received by the author was, is, or will be directly or indirectly related to the specific recommendations or views expressed

Clivemaund.com Disclosures

The quoted article represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks cannot be  only be construed as a recommendation or solicitation to buy and sell securities.

Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA), through its subsidiary Rocket Doctor Inc., has launched a new virtual health screening initiative for adults over the age of 60 in collaboration with EngageWell IPA. The program, known as the Healthy Aging Program, is backed by a five-year US$1 million grant from the CVS Health Foundation and aims to improve healthcare access for older adults in New York City.

The program provides no-cost virtual screenings for heart health, cognitive and memory function, and mental health. Board-certified physicians conduct consultations via phone or video and offer follow-up care plans tailored to each patient. Community Health Workers assist with navigation and help participants access necessary local services. Patients on Medicaid can access the service at no cost, while Medicare patients are covered through insurance.

Dr. William Cherniak, Founder and CEO of Rocket Doctor, stated in the press release, "We're proud to again partner with EngageWell to bring high-quality, proactive care directly into the homes of older adults across New York City." The pilot aims to reduce barriers related to language, digital literacy, and mobility, and to address healthcare access issues in underserved communities.

The launch follows Treatment.com AI's recent acquisition of Rocket Doctor, finalized earlier this year. Since then, Rocket Doctor has reported significant growth across its operations. In Alberta, Canada, patient volume increased by 112% year-over-year, with 36,779 patients served in the past 12 months. Physician participation also grew from 22 to 70 over the same period, a 218% rise.

Rocket Doctor has also entered into new partnerships, including a virtual care program with Central California Alliance for Health, which serves approximately 450,000 Medi-Cal members, and an initiative with Melanoma Canada to improve follow-up care for high-risk skin cancer patients. In recognition of its clinical innovation, Rocket Doctor was named a Top Clinical Innovator by the American Telemedicine Association and was featured at events hosted by Harvard Medical School and the AARP AgeTech Accelerator.

The parent company, Treatment.com AI, continues to evolve and integrate its AI-powered diagnostic engine, the Global Library of Medicine (GLM), across medical education, telehealth, and provider platforms. According to the company's July 2025 investor presentation, the GLM currently includes over 10,000 expert medical reviews and is designed to assist with diagnosing more than 1,000 diseases in real time. 

Telehealth Sector Faces New Standards and Growing Regulatory Demands

The virtual care and telehealth sector remained in a period of transition during mid-2025, as stakeholders navigated growing regulatory pressures, operational scrutiny, and efforts to redefine ethical practices across the industry.

On April 3, Fierce Healthcare published a retrospective analysis examining how the COVID-19 pandemic reshaped healthcare delivery in the United States. Jesse Ehrenfeld, M.D., immediate past president of the American Medical Association, emphasized that "you can't have a conversation about the last five years and not talk about telehealth." He noted a dramatic rise in adoption, with three-quarters of physicians offering telehealth by late 2023, compared to only one-quarter before the pandemic. Fierce Healthcare reported that this expansion improved access to care, especially for mental health services and patients in remote areas, and encouraged broader use of patient portals. However, experts like Patricia McGaffigan of the Institute for Healthcare Improvement advised that adoption must remain measured, stating, "it's important for us to proceed with a reasonable level of enthusiasm, but also a clear degree of caution."

The introduction of artificial intelligence tools into telehealth also drew attention. According to Ehrenfeld, "AI is coming into practice in a way that is really exciting," citing a 78% increase in physician usage of health-related AI tools from 2023 to 2024. Yet, regulatory gaps and concerns around responsible implementation continued. Fierce Healthcare noted that general-purpose AI models were sometimes used for clinical decisions, raising questions about patient safety and oversight.

According to a June 12 report from Future Market Insights, the global wireless healthcare asset management market was projected to increase from US$52.06 billion in 2025 to US$155.40 billion by 2035. The report attributed this growth to the widespread adoption of artificial intelligence (AI), Internet of Things (IoT), and real-time tracking tools within hospitals. These technologies were used to monitor high-value equipment such as infusion pumps and surgical instruments, improve maintenance scheduling, and enhance patient safety through predictive analytics.

The report also noted that cloud-based platforms enabled real-time equipment monitoring, predictive maintenance, and compliance tracking. It identified a trend toward integrating AI systems with electronic health records (EHRs) and hospital information systems (HIS) to support resource optimization and more informed clinical decisions.

Strategic Positioning in Virtual Care and AI Health Tools

The collaboration with EngageWell and the CVS Health Foundation aligns with Treatment.com AI's broader strategy to merge artificial intelligence with physician-led care models. The company's AI platform has been implemented in university clinical training programs, including the University of Minnesota Medical School, where it enabled OSCE testing of 240 students using AI-simulated patients. The institution estimates that the AI-driven platform could reduce exam costs by approximately 40%.

Rocket Doctor's model combines telehealth infrastructure with physician autonomy, allowing doctors to independently manage virtual clinics. As of July 2025, Rocket Doctor has facilitated care for over 600,000 patients across four Canadian provinces and three U.S. states, supported by a physician network of over 300 professionals.

Revenue generation is driven by a mix of per-appointment fees in the U.S. and Canada, monthly platform fees from physicians, and direct-to-consumer partnerships. According to Treatment's July 2025 presentation, these include pharmacy kiosks and device-enabled care stations used by independent provider associations.

The company has also attracted national attention through accelerator programs at institutions such as UC Berkeley and public recognition through speaking engagements and awards. These developments reinforce Treatment.com AI's role as a key player in expanding access to virtual care for aging and underserved populations through scalable, physician-led, AI-enhanced platforms.

Analyst Identifies Technical Rebound and Operational Strength at AI Healthtech Company

*On May 21, Technical Analyst Clive Maund published an assessment of Treatment.com AI Inc., highlighting what he described as the company's strategic positioning within the evolving artificial intelligence (AI) healthcare landscape.

Maund noted that Treatment.com AI had developed a physician-designed platform intended to address inefficiencies in healthcare by combining clinical intelligence, virtual care capabilities, and voice assistant technology into a unified system. He referred to the company's diagnostic tools — powered by the proprietary Global Library of Medicine (GLM) — as offering continuous availability and AI-driven voice interactivity intended to support clinical workflows.

He also referenced the company's Rocket Doctor subsidiary, describing it as a "Shopify for physicians" that allowed practitioners to launch remote clinics and expand access to virtual care. Maund cited the model's scalability as a factor in its relevance to the broader telehealth market.

From a technical standpoint, Maund observed that the company's stock had recently completed what he interpreted as a three-wave A-B-C correction pattern and was rising from a long-term base established over a 30-month period. He identified technical support levels that, in his view, marked a potential inflection point for the stock's movement.

In his analysis, Maund stated that recent volume patterns signaled growing investor interest, describing the accumulation since early 2024 as "supportive of a significant new uptrend." He outlined an initial target range of CA$1.08 to CA$1.12, with a secondary target of CA$4.00. Maund concluded that the combination of market positioning and technical indicators suggested, in his opinion, that it was "an excellent time to buy or add to positions in Treatment.com AI."

Ownership and Share Structure

According to Refinitiv, insiders own approximately 5.2% of Treatment.com AI. Institutions hold .81%. Retail investors own the remaining 94%.    

The company has 75,502,398 million outstanding common shares.  The market cap is approximately CA$29,068,423.20. 

Over the past 52 weeks, the company traded between CA$0.0471 and CA$0.9116 per share.